David Wirta
Ophthalmology · Newport Beach, CANPI 1255435822
Payments from drug & device makers
Across 826 payments — averaging $22,317 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10.5M
- Oyster Point Pharma, Inc.$1.6M
- Aerie Pharmaceuticals, Inc.$1.1M
- Glaukos Corporation$903K
- Alcon Research LLC$864K
- Novartis$677K
- plus $2.8M from 23 others
Across 264 payments — averaging $3133.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$405K
- Alcon Research LLC$199K
- Amneal Pharmaceuticals LLC$173K
- Kala Pharmaceuticals, Inc.$51K
- AbbVie$16
What the payments were for
- Consulting fees$52,89588%
- Speaking & faculty fees$3,2005%
- Travel & lodging$2,0673%
- Food & beverage$1,7753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 522 | $10,494,563 |
| Oyster Point Pharma, Inc. | 52 | $1,598,142 |
| Aerie Pharmaceuticals, Inc. | 14 | $1,127,856 |
| Glaukos Corporation | 57 | $902,991 |
| Alcon Research LLC | 30 | $863,683 |
| Novartis | 7 | $676,661 |
| Bausch & Lomb Americas Inc. | 6 | $634,657 |
| Kowa Research Institute, Inc. | 7 | $500,035 |
| Sight Sciences, Inc. | 12 | $294,561 |
| Dompe US, Inc. | 4 | $201,977 |
| Padagis US LLC | 3 | $183,750 |
| Shire North American Group Inc | 3 | $179,408 |
| Vanda Pharmaceuticals Inc. | 3 | $171,376 |
| Ocular Therapeutix, Inc. | 9 | $167,075 |
| Perrigo Company PLC | 5 | $89,650 |
| Amneal Pharmaceuticals LLC | 4 | $71,293 |
| Boehringer Ingelheim | 4 | $65,290 |
| Sun Pharmaceutical Industries Inc. | 8 | $58,998 |
| Mallinckrodt Hospital Products Inc. | 4 | $58,400 |
| Kala Pharmaceuticals, Inc. | 5 | $39,060 |
| Alcon | 20 | $23,282 |
| Dompe Farmaceutici S.p.a. | 1 | $17,990 |
| Mallinckrodt Enterprises LLC | 1 | $3,500 |
| Osmotica Pharmaceutical Corp. | 4 | $3,429 |
| Boehringer Ingelheim International GmbH | 37 | $3,043 |
| Vertical Pharmaceuticals, LLC | 1 | $2,750 |
| Thea Pharma Inc. | 1 | $48 |
| Harrow Eye, LLC | 1 | $47 |
| Amgen | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,433,539 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 103 | $765 |
| Timolol Maleate | 43 | $280 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Newport Beach
- Sheri RowenNewport Beach$1.8M
- Ehsan SadriNewport Beach$1.3M
- Nisha AcharyaSan Francisco$33M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.